Your browser doesn't support javascript.
loading
To Expand the Evidence Base About Harms from Tests and Treatments.
Korenstein, Deborah; Harris, Russell; Elshaug, Adam G; Ross, Joseph S; Morgan, Daniel J; Cooper, Richelle J; Cho, Hyung J; Segal, Jodi B.
Afiliação
  • Korenstein D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. korenstd@mskcc.org.
  • Harris R; UNC School of Medicine, Chapel Hill, NC, USA.
  • Elshaug AG; Melbourne School of Population and Global Health and Melbourne Medical School, The University of Melbourne, Melbourne, Australia.
  • Ross JS; The Brookings Institution, Washington DC, USA.
  • Morgan DJ; Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Cooper RJ; Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Cho HJ; UCLA Department of Emergency Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Segal JB; Department of Quality and Safety, NYC Health and Hospitals, New York, NY, USA.
J Gen Intern Med ; 36(7): 2105-2110, 2021 07.
Article em En | MEDLINE | ID: mdl-33479928
ABSTRACT
Rigorous evidence about the broad range of harms that might be experienced by a patient in the course of testing and treatment is sparse. We aimed to generate recommendations for how researchers might more comprehensively evaluate potential harms of healthcare interventions, to allow clinicians and patients to better include this evidence in clinical decision-making. We propose seven domains of harms of tests and treatments that are relevant to patients (1) physical impairment, (2) psychological distress, (3) social disruption, (4) disruption in connection to healthcare, (5) labeling, (6) financial impact, and (7) treatment burden. These domains will include a range of severity of harms and variation in timing after testing or treatment, attributable to the service itself or a resulting care cascade. Although some new measures may be needed, diverse data and tools are available to allow the assessment of harms comprehensively across these domains. We encourage researchers to evaluate harms in sub-populations, since the harms experienced may differ importantly by demographics, social determinants, presence of comorbid illness, psychological state, and other characteristics. Regulators, funders, and editors might require either assessment or reporting of harms in each domain or require justification for inclusion and exclusion of different domains.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article